Oral involvement in primary Sjögren syndrome
Section snippets
Participants and procedures
We recruited nine physicians at rheumatology or oral medicine clinics, whom either we or the SSF identified as dealing with a high volume of patients with SS, to participate in this study. We asked the nine physicians to identify from their records all patients classified as having PSS according to the 2002 AECG criteria.19 We asked physicians who had 100 or fewer patients with PSS to recruit all eligible patients for the survey. We asked physicians who had more than 100 eligible patients to
RESULTS
Of 547 surveys sent through participating physicians' offices, respondents returned 281 (51 percent). Of these, four were duplicates, and we excluded them. Of the 8,694 surveys sent to SSF patients, 3,939 (45 percent) were returned. Control subjects returned 630 surveys.
DISCUSSION
To our knowledge, our data represent the largest survey results and the most comprehensive picture of oral involvement available for patients with PSS. Authors of previously published case series have provided valuable knowledge of the natural history and manifestations of PSS but have not reported detailed information on the disorder's oral aspects.13, 14, 15, 16, 17, 18 For example, Pertovaara and colleagues13 reported about complaints of xerostomia (77 percent) and parotid swelling (32
CONCLUSION
Investigators have published numerous reports of various oral aspects of SS.5, 6, 7, 8, 9, 10, 11, 12 However, most have examined relatively small groups or focused on a particular aspect of the condition. We believe our report is the first to evaluate a large number of subjects (> 1,000) and the first to attempt to capture the full spectrum of the condition's oral signs and symptoms, as well as its effect on patients' general health and well-being. Our results clearly demonstrate the marked
REFERENCES (33)
- et al.
Salivary dysfunction and quality of life in Sjögren syndrome: a critical oral-systemic connection
JADA
(2008) - et al.
Clinical evolution, and morbidity and mortality of primary Sjögren's syndrome
Semin Arthritis Rheum
(2000) - et al.
Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system
J Pain Symptom Manage
(1997) - et al.
Xerostomia: evaluation of a symptom with increasing significance
JADA
(1985) - et al.
Xerostomia: etiology, recognition and treatment
JADA
(2003) - et al.
Clinical manifestations and early diagnosis of Sjögren syndrome
Arch Intern Med
(2004) - et al.
Oral manifestations of Sjögren's syndrome
J Dent Res
(2008) - et al.
Sjogrens syndrome: the non-apoptotic model of glandular hypofunction
Rheumatology (Oxford)
(2006) - et al.
The risk of lymphoma development in autoimmune diseases: a meta-analysis
Arch Intern Med
(2005) - et al.
Glandular function in Sjögren syndrome: assessment with dynamic contrast-enhanced MR imaging and tracer kinetic modeling—initial experience
Radiology
(2008)
Supra-gingival microbiota in Sjögren's syndrome
Clin Oral Investig
Salivary gland parameters and clinical data related to the underlying disorder in patients with persisting xerostomia
Eur J Oral Sci
Oral and dental aspects of Sjögren's syndrome
J Ir Dent Assoc
Evaluation of palatal saliva flow rate and oral manifestations in patients with Sjögren's syndrome
Oral Dis
Progression of salivary gland dysfunction in patients with Sjogren's syndrome
Ann Rheum Dis
Oral and salivary parameters in patients with rheumatic diseases
Acta Odontol Scand
Cited by (0)
Disclosure. The medical authors of this article—Drs. Fox, Bowman, Segal and Vivino—received consultancy payments from Genentech, South San Francisco, Calif., for their time spent on questionnaire and project design, project implementation and data analysis in preparation for publication.
The study described in this article was funded by Genentech, South San Francisco, Calif. Data collection and analysis were performed by Harris Interactive, New York City.
The authors thank the Sjögren's Syndrome Foundation, Bethesda, Md., for its enthusiastic support. In particular, they thank Steven Taylor, chief executive officer, and the foundation members who took part in this survey. The authors also thank the rheumatologists and oral medicine specialists—Drs. Steven Carsons, Stuart Kassan, Athena Papas, Nelson Rhodus, Daniel Small, Harry Spiera and Neil Stahl—who aided them, as well as these doctors' patients who participated in this project.
- 1
Dr. Fox is the president, PC Fox Consulting, Via Monterione 29, 06038 Spello (PG), Italy
- 2
Dr. Bowman is a consultant rheumatologist, University Hospital Birmingham (Selly Oak), Department of Rheumatology, Birmingham, England.
- 3
Dr. Segal is an associate professor, Department of Medicine, University of Minnesota Medical School, Minneapolis.
- 4
Dr. Vivino is a clinical associate professor, Division of Rheumatology, Hospital of the University of Pennsylvania, Philadelphia.
- 5
Dr. Murukutla is a research manager, Health Care and Policy Research, Harris Interactive, New York City.
- 6
Ms. Choueiri is a research associate, Health Care and Policy Research, Harris Interactive, New York City.
- 7
Dr. Ogale is a health economist, Genentech, South San Francisco, Calif.
- 8
Dr. McLean is a medical director, Genentech, South San Francisco, Calif.